Invited Commentary on Dubé et al. (Perceptions of Equipoise,Risk/Benefit Ratios,and “Otherwise Healthy Volunteers” in the Context of Early-Phase HIV Cure Research in the United States—A Qualitative Inquiry): Are HIV-Infected Candidates for Participation in Risky Cure-Related Studies Otherwise Healthy?
Restricted accessResearch articleFirst published online February, 2018
Invited Commentary on Dubé et al. (Perceptions of Equipoise,Risk/Benefit Ratios,and “Otherwise Healthy Volunteers” in the Context of Early-Phase HIV Cure Research in the United States—A Qualitative Inquiry): Are HIV-Infected Candidates for Participation in Risky Cure-Related Studies Otherwise Healthy?
Barré-SinoussiF.RossA. L.DelfraissyJ. F. (2013). Past, present and future: 30 years of HIV research. Nature Reviews Microbiology, 11, 877-883.
2.
DeeksS. G.LewinS. R.RossA. L.AnanworanichJ.BenkiraneM.CannonP.. . . ZackJ. (2016). International AIDS Society global scientific strategy: Towards an HIV cure 2016. Nature Medicine, 22, 839-850. doi:10.1038/nm.4108
3.
DubéK.DeeL.EvansD.SyllaL.TaylorJ.BrownB.… & TuckerJ. D. (2017). Perceptions of Equipoise, Risk–Benefit Ratios, and “Otherwise Healthy Volunteers” in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. Journal of Empirical Research on Human Research Ethics, 13, 3–17. doi:10.1177/1556264617734061
4.
EyalN. (2017). How to keep high-risk studies ethical: Classifying candidate solutions. Journal of Medical Ethics, 43, 74-77.
